 |
 | Vissza |
Goldman Jonathan W; Dvorkin Mikhail; Chen Yuanbin; Kollaborációs szervezet: CASPIAN investigators; Losonczy György; Horváth Zsolt; Pajkos Gábor; Bogos Krisztina; Somfay Attila; Pápai Székely Zsolt; Sárosi Veronika; Fülöp Andrea; Laczó Ibolya; Kósa Judit; Telekes András; Csánky Eszter; Somogyiné Ezer Éva; Pápai Zsuzsanna (kollab. közrem.):
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
LANCET ONCOLOGY, 22 (1).
pp. 51-65.
ISSN 1470-2045
(2021)
Paz-Ares Luis; Dvorkin Mikhail; Chen Yuanbin; Reinmuth Niels; Hotta Katsuyuki; Trukhin Dmytro; Statsenko Galina; Hochmair Maximilian J; Özgüroğlu Mustafa; Ji Jun Ho; Voitko Oleksandr; Poltoratskiy Artem; Ponce Santiago; Verderame Francesco; Havel Libor; Bondarenko Igor; Kazarnowicz Andrzej; Losonczy György; Conev Nikolay V; Armstrong Jon; Byrne Natalie; Shire Norah; Jiang Haiyi; Goldman Jonathan W; Kollaborációs szervezet: CASPIAN investigators; Somfay Attila; et al. (kollab. közrem.):
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : a randomised, controlled, open-label, phase 3 trial.
LANCET, 394 (10212).
pp. 1929-1939.
ISSN 0140-6736
(2019)
